Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has successfully completed dosing of its latest cohort in its Phase 1/2 UTI/urosepsis clinical trial, evaluating RECCE® 327 (R327) at fast infusion rates.
An independent safety committee will now review and evaluate the comprehensive data from the four-subject cohort — dosed with RECCE® 327 at 3,000mg over 20 minutes — with recruitment for the next cohort already underway.
Data from this trial is expected to pave the way for a Phase 2 UTI/urosepsis efficacy trial, potentially establishing R327 as a frontline treatment.
The administration of antibiotics via rapid intravenous infusions is a proven safe and effective method of administration, impacting patient treatment, wait times, and nursing workloads globally.
Recce CEO James Graham said: "Completing dosing for our latest cohort marks another milestone in our journey advancing R327 as a potential frontline treatment for UTI/urosepsis. We are dedicated to delivering impactful solutions to combat infectious diseases and improve global health outcomes globally."